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Abstract The present study reports animal immuno-toxicological data of pulmonary vaccina-
tion against inactivated seasonal inﬂuenza. Its aims were (i) to monitor the temporal kinetics
of lung inﬂammation in normal mice over a period of 2 weeks following pulmonary vaccination
in order to assess the risk of chronic lung inﬂammation, (ii) to evaluate the impact of pul-
monary vaccination on the asthmatic phenotype in an established allergen-sensitized murine
model of asthma. Both sets of experiments were performed using high doses of split inﬂuenza
virus vaccine. In the ﬁrst part of this study, we showed that pulmonary inﬂuenza vaccina-
tion induced a slight local inﬂammatory response which was limited in duration since it was
no longer observed at 2 weeks post-vaccination. At this time point, it has previously been
shown that the immunogenic efﬁcacy was maintained. In the second part, we demonstrated
that pulmonary inﬂuenza vaccination did not signiﬁcantly exacerbate the cardinal features of
asthma, i.e., allergen-speciﬁc IgE formation, the development of airway hyperreactivity (AHR)
and eosinophilic airway inﬂammation. Our data therefore suggest that the overall immuno-
toxicological proﬁle of pulmonary vaccination against seasonal inﬂuenza was acceptable, even
in an animal model of pulmonary hypersensitivity.
© 2008 Elsevier Ltd. All rights reserved.
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Introduction
Inﬂuenza virus is a respiratory pathogen that causes yearly
epidemics resulting in high rates of morbidity and mortality
[1]. Moreover, a virulent strain of avian inﬂuenza A (H5N1)
currently represents a major pandemic threat [2]. In this
light, effective prevention of inﬂuenza is the ultimate goal,
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and new vaccination strategies are being investigated to
improve efﬁcacy, coverage and safety. As inﬂuenza virus nat-
urally infects the host through the mucosal surface of the
upper respiratory tract, vaccines delivered by the respira-
tory route are promising since they might not only induce
systemic but also mucosal immunity [3,4].
Aerosol administration of drugs or vaccines is technically
not demanding, non-invasive, and thus readily accepted by
patients. This is best illustrated by the fact that more than 4
million school-age children in Mexico have received measles
vaccination by pulmonary aerosol with no signiﬁcant adverse
events reported [5,6]. Pulmonary aerosol vaccination could
potentially be easily used in rapid mass-immunization cam-
paigns. Therefore, it could be extremely valuable in the
case of an inﬂuenza pandemic, or for universal vaccina-
tion of children with the seasonal inﬂuenza vaccine, which
could signiﬁcantly reduce the spread of inﬂuenza in the
community [7—9]. Interestingly, intranasal live-attenuated
inﬂuenza vaccine (LAIV) appears to have superior efﬁcacy to
existing injectable vaccines, and is safe for children at least
18 months of age [10,11]. Pulmonary inactivated inﬂuenza
vaccination is another strategy which, although still more
experimental, has already shown great promise [12,13].
One of the main safety issues regarding pulmonary
inﬂuenza vaccination is related to the induction of an
immune response in the respiratory tract, since this could
possibly trigger chronic inﬂammatory responses or exac-
erbate pre-existing lung diseases, such as asthma. An
additional safety concern for this route of immunization
will arise from the need of an adjuvant for increasing the
immunogenicity of pandemic H5 inﬂuenza antigen [2]. Any
new vaccination strategy targeting the respiratory tract
should therefore be cleared of the allegation of deleterious
inﬂammation as well as exacerbation of chronic inﬂamma-
tory airway disorders. In the case of LAIV, safety concerns
in asthma patients have been put to rest by a large study
by Fleming et al. [14]. However, for pulmonary vaccination
with inactivated split inﬂuenza virus, there are currently no
clinical or experimental data available.
We therefore aimed to address two major safety con-
cerns: ﬁrst, an inﬂammatory reaction to the seasonal
vaccine should be limited in duration and magnitude; sec-
ond, intra-pulmonary vaccination should not exacerbate a
pre-existing asthmatic airway disease. To address the ﬁrst
question, we monitored the temporal kinetics of lung inﬂam-
matory markers in normal mice over a period of 2 weeks
following pulmonary vaccination. The second set of exper-
iments was performed in a well established murine model
of allergen-induced airway disease. High doses of split virus
seasonal inﬂuenza vaccine were applied in both studies.
Materials and methods
Treatment protocol
All experimental procedures were approved by the insti-
tutional animal ethics committee. Female BALB/c mice
(6—8 weeks, Harlan) were immunized as described in
Table 1. To investigate the short- and long-term safety
of pulmonary inﬂuenza vaccination in non-asthmatic ani-
mals, mice were ﬁrst primed on day 0 by intranasal
(i.n.) instillation with a combination of three inacti-
vated whole virion inﬂuenza strains (5g hemagglutinin
(HA)/strain; A/Wyoming/3/2003, A/New Caledonia/20/99,
B/Jiangsu/10/2003, GSK Biologicals, Belgium) to generate
a background immunity (IN priming). The actual inﬂuenza
vaccination was performed on day 39 by an intratracheal
(i.t.) booster immunization with high vaccine doses of
either a combination of three split virion inﬂuenza strains
(3g HA/strain, 50l/instillation, same strains as for IN
priming) or one split virion inﬂuenza strain (12g HA,
50l/instillation, A/Wyoming/3/2003) (IT boost).
Allergen-sensitization
In a second set of experiments, we investigated the safety
of pulmonary inﬂuenza vaccination in an established murine
model of asthma [15—17]. The mice were vaccinated against
inﬂuenza according to the protocol mentioned above,
to which an allergen-sensitization/challenge protocol was
added. Mice were systemically sensitized on days 10 and
23 by intraperitoneal injections of 20g ovalbumin (OVA,
Grade VI, Sigma, USA), emulsiﬁed in 2mg of aluminium
hydroxide (AlumInject; Pierce, Rockford, IL, USA) in a total
volume of 200l (sensitization). All OVA-sensitized groups
were challenged with aerosolized OVA (100mg/10ml, Grade
V; nebulized by Medical Assistance System) for 20min each
day, on days 37—39 (challenge).
Negative controls involved exposure to PBS instead of
OVA or inﬂuenza vaccine. Positive controls for lung inﬂam-
mation were sham-primed with PBS and i.t. instilled with
LPS (20g, 50lo fa4 0 0 g/ml solution, Escherichia coli
O111:B4, Sigma).
Broncho-alveolar lavage (BAL)
At different time points, i.e., 4h, 36h, 72h, 7 days and
14 days after the i.t. booster immunization in the normal
mice, or on day 41 in the allergen-sensitized mice, the lung
was lavaged twice with 0.8ml PBS, as previously described
[15]. Cells of both aliquots were pooled; the total number
of live cells recovered by lavage was determined by the
trypan blue exclusion method, and differential cell counts
were performed on cytocentrifuge preparations stained with
Diff-Quick (Dade NV/SA).
Measurement of soluble biochemical components
of BAL
All assays were performed in the BAL supernatants
of the ﬁrst aliquot. TNF- and serum albumin levels
were measured by ELISA according to the manufactur-
ers’ instructions. TNF- ELISA was performed using a
Pharmingen OptEia kit (PharMingen) with a detection
limit of 23pg/ml. Mouse albumin ELISA was performed
using a commercial kit (Bethyl Laboratories, Montgomery,
TX, USA) with a detection limit of 11ng/ml. BAL
total protein content was assessed spectrophotometrically
using a commercial kit (Systemes Technicon, Doumon,
France). BAL lactate dehydrogenase (LDH) activity was
assessed spectrophotometrically by monitoring the reduc-2362 A. Minne et al.
Table 1 Immunization and sensitization protocols
Group IN priming (day 0) IT boost (day 39)
A
PBS PBS PBS
Flu 9g Flu Flu 9g (trivalent)
Flu 12g Flu Flu 12g (monovalent)
LPS PBS LPS
Group IN priming (day 0) Sensitization/challenge (days 10,23/37—39) IT boost (day 39)
B
PBS/OVA/PBS PBS OVA PBS
Flu/OVA/PBS Flu OVA PBS
Flu/OVA/ﬂu 9g Flu OVA Flu 9g (trivalent)
Flu/OVA/ﬂu 12g Flu OVA Flu 12g (monovalent)
PBS/OVA/LPS PBS OVA LPS
(A) To investigate the safety of pulmonary inﬂuenza vaccination in na¨ ıve animals, mice were primed on day 0 by intranasal (i.n.) instilla-
tion of three inactivated whole virion inﬂuenza strains (5g hemagglutinin (HA)/strain; A/Wyoming/3/2003, A/New Caledonia/20/99,
B//Jiangsu/10/2003) (IN priming). Vaccination was performed on day 39, the mice then received an intratracheal (i.t.) booster
immunization with high vaccine doses of three split virion inﬂuenza strains (3× 3g HA/strain, 9g HA in total, 50l/instillation,
same strains as for IN priming) or one split virion inﬂuenza strain (12g HA, 50l/instillation, A/Wyoming/3/2003) (IT boost). (B) To
investigate the safety of pulmonary inﬂuenza vaccination in allergen-sensitized mice, animals were immunized as mentioned above.
Additionally, mice were systemically sensitized against ovalbumin (OVA) on days 10 and 23 (sensitization), and were challenged with
aerosolized OVA on days 37—39 (challenge). Negative controls involved exposure to PBS instead of inﬂuenza vaccine or OVA, and a
positive control for lung inﬂammation was sham-primed with PBS and i.t. instilled with LPS (20g).
tion of NAD+ at 340nm in the presence of lactate
[18].
Lung histology
36h after the i.t. booster immunization in normal mice, the
lung lobes were instilled with 1ml 50% TissueTek (Reichart-
Jung, Nuloch, Germany) in PBS. The left lobe was removed,
embedded in TissueTek cryomatrix and frozen by rapid
immersion in liquid nitrogen, and preserved at −70 ◦C.
Sections (8m) were stained with haematoxylin—eosin, cov-
erslipped, and examined by light microscopy.
Immunoglobulins
Total IgG and IgA titres in BAL supernatants were determined
by ELISA, as described [13]. Standard curves were consti-
tuted of mouse IgG (Chrompure, Jackson ImmunoResearch)
or puriﬁed mouse myeloma protein IgA (MP Biomedicals,
Aurora,OH,USA).ThequantiﬁcationlimitsoftheIgGandIgA
assaywere0.9ng/mland2.4ng/ml,respectively.Serumlev-
els of OVA-speciﬁc IgE were measured by ELISA, as previously
described [15]. Levels of OVA-speciﬁc IgE were calculated
in relation to pooled standards generated in our laboratory
and expressed as arbitrary lab units per ml (LU/ml). The
detection limit of this assay was 12LU/ml.
In vivo airway reactivity
On day 40, lung function was measured by whole-body
plethysmography (WBP, EMKA Technologies, F), as previously
reported [16]. Animals were exposed to aerosolized PBS for
baseline reading and then to increasing concentrations of
methacholine (MCh) (6—50mg/ml). Airway reactivity was
expressed as the increase of enhanced pause (Penh) val-
ues for each concentration of MCh relative to baseline Penh
values.
Statistical analysis
Values for all measurements were expressed as
mean±standard error of the mean. Groups of mice
were comprised of four to six animals. Data were analyzed
by using the JMP version 4.0.2 and GraphPad Prism version
4.00 software programs. Pairs of groups were compared by
one-way ANOVA with Tukey’s multiple comparison post-test.
Statistical signiﬁcance was set at P<0.05.
Results
Effect of pulmonary inﬂuenza vaccination in
normal mice
BAL cell population and lung histology
As a marker for pulmonary inﬂammation, we analyzed the
cellular distribution in BAL ﬂuid after vaccination. Pul-
monary inﬂuenza vaccination in normal mice increased BAL
total cell counts, but this was only statistically signiﬁcant
at days 7 and 14 after vaccine administration (Fig. 1A). This
increase in total cells was due to the recruitment of lym-
phocytes, which steadily increased over time to reach a
peak 7 days post-immunization (Fig. 1B). Pulmonary deliv-
ery of inﬂuenza vaccine induced a slight and transient inﬂux
of neutrophils that peaked at 36h and faded by day 7
(Fig. 1C). This inﬂux was not pronounced on histological
slides from the lung at 36h (Fig. 2). In contrast to pul-Safety of pulmonary inﬂuenza vaccination 2363
Figure 1 Mice were immunized as described in Table 1A. At different time points following the intratracheal boost, lung was
lavaged, and the BAL cells differentiated and counted. Total cell counts (A), lymphocytes counts (B), neutrophils counts (C) and
macrophages counts (D) are expressed as cells×103/ml. * indicates groups whose values are signiﬁcantly different from those of
the other groups. § indicates groups whose values are signiﬁcantly different from those of the PBS mice. One symbol indicates
signiﬁcant differences (P<0.05), two symbols indicate highly signiﬁcant differences (P<0.01).
monary inﬂuenza vaccination, pulmonary delivery of LPS
as positive control generated a sharp increase in total
cell numbers, which were maintained signiﬁcantly above
the negative control group from 36h to 14 days after
delivery (Fig. 1A). The early cellular inﬂux was almost
exclusively composed of neutrophils with a peak after
36h and persisted for at least 72h after LPS instillation
(Fig. 1C).
The histological lung slides of inﬂuenza vaccinated mice
at 36h did not show a striking difference with the negative
controls (Fig. 2). The ﬂu 12g group showed some minor
indications of a possible alveolar proteinosis (slightly reddish
veil). This was further investigated.
BAL TNF- levels
To address the question whether pulmonary vaccination
might induce pro-inﬂammatory cytokines, we monitored the
TNF- level in BAL ﬂuid as marker for local inﬂammation.
Pulmonary inﬂuenza vaccination with either 9go r1 2gH A
did not affect BAL TNF- level at any time point following
i.t. vaccine administration, when compared to negative con-
trols (PBS, Fig. 3). LPS instillation as positive control induced
a sharp and highly signiﬁcant increase of TNF- in BAL 4h
after administration (P<0.01 vs. other groups, Fig. 3). At
later time points, LPS-induced TNF- production was down-
regulated and reached negative control levels by 36h after
pulmonary instillation.
Figure 2 Effect of vaccination with whole and split inﬂuenza vaccine on lung tissue integrity. Mice were immunized as described
in Table 1A. The lung was removed 36h after the IT boost immunization for histology. (A) negative controls (PBS), (B) ﬂu 9g and
(C) ﬂu 12g.2364 A. Minne et al.
Figure 3 Effect of pulmonary inﬂuenza vaccination on TNF-
level in BAL. Mice were immunized as described in Table 1A.
At different time points following the IT boost, the lung was
lavaged, and BAL levels of TNF- were measured by ELISA. **
P<0.01 vs. all other groups.
BAL biochemical parameters
For further analysis of local effects caused by the inﬂuenza
vaccination, we measured several additional biomarkers in
the BAL ﬂuid.
LDH activity. Lactate dehydrogenase being a strictly intra-
cellular enzyme, LDH activity in BAL was measured as a
marker of epithelial cell integrity. The LDH activity in BAL
ﬂuids of pulmonary inﬂuenza vaccinated mice and nega-
tive controls (PBS) were similar at 4h and 14 days after i.t.
administration. In between these two time points, inﬂuenza
vaccination induced a slight increase in BAL LDH activity,
peaking at 36h and plateauing until 72h. LPS treatment
induced a signiﬁcant increase of LDH activity in BAL ﬂuids at
36h and 72h post-administration (P<0.01 vs. other groups,
Fig. 4A).
Protein content. Pulmonary inﬂuenza vaccination did not
signiﬁcantly interfere with BAL total protein levels com-
pared to negative controls until 14 days post-administration
(Fig. 4B). A small increase was observed at 36h and 72h, but
total protein levels were decreased at later time points. The
temporal kinetic of BAL total protein content in LPS-treated
control animals was comparable to that observed for LDH
activity in the same animals, i.e., a signiﬁcant increase at
36h and 72h post-administration, which was downregulated
at later time points.
Albumin content. The albumin content in BAL was used
as a marker of the permeability of the pulmonary tissue,
from the vascular bed to the airway epithelium. The albumin
content in BALs of inﬂuenza i.t. vaccinated mice was not sig-
niﬁcantly different from that of negative controls. However,
Figure 4 Effect of pulmonary inﬂuenza vaccination on BAL (A) lactate dehydrogenase (LDH) activity, (B) total protein content,
(C) serum albumin content and (D) total immunoglobulin (Ig) content. Mice were immunized as described in Table 1A. At different
time points following the intratracheal boost, the lung was lavaged and BAL levels of LDH, total proteins, serum albumin and total
Ig were measured. * indicates groups whose values are signiﬁcantly different from those of the other groups. § indicates groups
whose values are signiﬁcantly different from those of the PBS mice. † indicates groups whose values are signiﬁcantly different from
those of the LPS mice. One symbol indicates signiﬁcant differences (P<0.05), two symbols indicate highly signiﬁcant differences
(P<0.01).Safety of pulmonary inﬂuenza vaccination 2365
a clear trend was noticeable: the albumin content steadily
increased until 72h post-administration and was then down-
regulated. The LPS-treated controls showed a signiﬁcant
increase in albumin BAL levels at 36h post-administration,
this was then decreased from 72h on.
Immunoglobulin content. The total Ig content in BALs of
inﬂuenza i.t. vaccinated mice increased progressively with
time and was signiﬁcantly higher than that of negative con-
trols from 36h post-administration on (P<0.01, Fig. 4C).
The total Ig content in BAL of animals treated i.t. with LPS
increased to the same extent as that of inﬂuenza vaccinated
mice until 7 days post-administration. At this time point the
Ig content was signiﬁcantly lower than in inﬂuenza vacci-
nated mice, but was still signiﬁcantly superior to that of
negative controls (P<0.01, Fig. 4C).
Effect of pulmonary inﬂuenza vaccination in
allergen-sensitized and challenged mice
Airway reactivity
OVA sensitization and allergen airway challenges caused
development of in vivo airway hyperreactivity (AHR) in
response to unspeciﬁc airway provocation with metha-
choline as shown by the increase in maximal Penh values
compared to negative controls (Fig. 5). Inﬂuenza vaccina-
tion subsequent to OVA sensitization/challenge reduced the
development of AHR, as demonstrated by the reduction in
maximal Penh values when compared to PBS/OVA/PBS mice.
This effect was also observed with the pulmonary instillation
of LPS following allergen-sensitization/challenge (Fig. 5).
BAL cell population
BAL cells of negative control animals (PBS, Fig. 6) were
identiﬁed as mainly macrophages. OVA airway challenges
of sensitized mice caused allergen-induced airway inﬂam-
mation characterized by a highly signiﬁcant inﬂux of
eosinophils, lymphocytes and macrophages into the lung
(Fig. 6). Pulmonary inﬂuenza vaccination with 9go r1 2g
of hemagglutinin (HA) following ﬂu i.n. priming and OVA sen-
sitization/challenge did not signiﬁcantly alter the cellular
pattern of BAL ﬂuids when compared to the ﬂu/OVA/PBS
group (Fig. 6). Only a slight, but not signiﬁcant, increase
Figure 5 Mice were immunized and sensitized as described
in Table 1B. On day 40, in vivo airway reactivity in response to
increasing doses of aerosolized methacholine was measured by
means of whole-body plethysmography.
of neutrophilic accumulation was observed. In contrast, the
intratracheal instillation of LPS clearly affected BAL cell
counts, inducing a highly signiﬁcant inﬂux of cells, mainly
differentiated as neutrophils (P<0.001 vs. other groups,
Fig. 6).
BAL TNF- level
Pulmonary inﬂuenza vaccination, with 9go r1 2 g HA,
following i.n. priming and OVA sensitization and allergen air-
way challenges did not signiﬁcantly affect the BAL TNF-
level as a marker of early airway inﬂammation. In contrast,
the instillation of LPS to OVA-sensitized/challenged mice
induced a signiﬁcant increase of BAL TNF- levels (Fig. 7).
Serum allergen-speciﬁc IgE
OVA sensitization induced a highly signiﬁcant increase in
serum levels of OVA-speciﬁc IgE compared to negative con-
trols (PBS, Fig. 8). Pulmonary administration of inﬂuenza
vaccine following OVA sensitization/challenge did not sig-
niﬁcantly affect OVA-speciﬁc IgE levels. However, i.n. ﬂu
priming induced a trend for decreased OVA-speciﬁc IgE lev-
els, which was enhanced by subsequent administration of
Figure 6 Mice were immunized as described in Table 1B. On day 41, the lung was lavaged and the cells recovered were stained
and differentiated. Cell counts are expressed as cells×103/ml. # indicates groups whose values are signiﬁcantly different from
those of the PBS/OVA/PBS group. One symbol indicates signiﬁcant differences (P<0.05), two symbols indicate highly signiﬁcant
differences (P<0.01). ** P<0.01 vs. all other groups, † P<0.05 vs. PBS/OVA/LPS.2366 A. Minne et al.
Figure 7 Mice were immunized and sensitized as described in
Table 1B. On day 41, broncho-alveolar lavages were performed.
BAL levels of TNF- were measured by ELISA. ** P<0.01 vs. all
other groups.
Figure 8 Mice were immunized and sensitized as described in
Table 1B. On day 41, blood samples were collected. Serum levels
of OVA-speciﬁc IgE were measured by means of ELISA. ** P<0.01
vs. all other groups. ND: below detection limit (12LU/ml).
inﬂuenza vaccine into the lung. On the contrary, intratra-
cheal instillation of LPS to OVA-sensitized/challenged mice
signiﬁcantly increased serum OVA-speciﬁc IgE levels (Fig. 8).
Discussion
The aim of the present study was to evaluate the local
effects of pulmonary vaccination with high doses of split
virus inﬂuenza vaccine in non-asthmatic and asthmatic
mice. The doses used in our experiments were twofold (3×
3g HA, trivalent) or eight fold (12g HA, monovalent),
respectively, the usual dose administered to elicit signiﬁ-
cant immune responses in mice against seasonal inﬂuenza
antigens (1.5g HA/strain=1/10th of the human dose) [13].
First, we investigated the temporal kinetics of different
lung inﬂammatory markers in normal mice over a period
of 2 weeks following pulmonary inﬂuenza vaccination or
LPS administration for the positive control. Our obser-
vations clearly conﬁrmed the established cascade of the
innate immune response to an antigenic viral fragment.
This response is initiated by an early production of pro-
inﬂammatory mediators, such as TNF-, IL-1 and IL-8 (MIP-2
and KC in mice), causing upregulation of adhesion molecules
(for leukocytes) on the vascular endothelium and on the dis-
tal airway epithelium, and resulting in the recruitment of
neutrophils into the alveolar compartment and activation
of lung macrophages [19]. Degranulation of neutrophils and
macrophages results in the release of elastases that stimu-
late macrophages to produce LTB4 [20] cathepsin G, reactive
oxygen species (ROS), and proteinases [21]. These pro-
teinases and ROS damage the epithelium [22] and increase
the permeability of the bronchial mucosa, resulting in pro-
tein exudation into the airways [23].
This temporal kinetic of lung inﬂammation markers was
particularly evident in the LPS-treated mice, in which a
strong production of TNF- preceded a massive inﬂux of
neutrophils, which on its turn headed signiﬁcant LDH and
total protein activity in BAL (Figs. 1, 3 and 4A and B). This
pattern was also observed in inﬂuenza vaccinated mice, but
the response was signiﬁcantly lower in its quantity and, most
importantly, limited in time. The notion of reversibility of
the inﬂammatory response caused by vaccination is most
crucial. Due to its function as a defence mechanism, inﬂam-
mationisakeyeffectorprocessinanykindofinnateimmune
response. This can be illustrated by the ﬁnding that soluble
antigens and low doses of particulate antigens that do not
induce pulmonary inﬂammation do not produce a primary
immune response [24]. However, inﬂammation is a double-
edged sword as it also may damage the host tissues if its
activity is sustained. Our data demonstrated that, at a time
point at which the immune response to the vaccine is still
active (i.e., 14 days post-immunization), the non-speciﬁc
inﬂammatory reaction has already been turned off.
The immunological efﬁcacy of pulmonary inﬂuenza vac-
cination at 14 days post-immunization was suggested by
the signiﬁcant increase in levels of cells and total protein
content in BALs of inﬂuenza vaccinated mice at this time
point (Figs. 1A and 4B). The residual BAL cells were identi-
ﬁed as lymphocytes (Fig. 1B), and the residual increase in
total proteins in BAL 14 days after immunization consisted
mostlyofimmunoglobulins(IgGandIgA,Fig.4D).Thesetotal
Igs steadily increased in BAL by time following pulmonary
inﬂuenza vaccination and already reached highly signiﬁcant
levels when compared to negative controls (PBS) 36h after
vaccination and for the rest of the observation period. This
corroborates previous data, obtained with smaller vaccine
doses, in which we demonstrated that the pulmonary route
induced local production of speciﬁc immunoglobulins [13].
This previous study demonstrated that the pulmonary route
is an effective route of immunization to induce a broad
immune response to an inﬂuenza vaccine [13].
Immunoglobulins are not the only sources of proteins in
BAL. Proteins can also transudate from the vascular bed
into the broncho-alveolar lumen when the epithelial per-
meability is increased. In the current study, the increase of
LDH levels in BAL indicated epithelial damage, resulting in
increased permeability as shown by a small concurrent peak
in BAL total proteins at 72h post-immunization. These pro-
teins were identiﬁed to mainly originate from the plasma
(Fig. 4C). Active resolution of inﬂammation is crucial ifSafety of pulmonary inﬂuenza vaccination 2367
injury to the lung is to be avoided. The plasma proteins that
exit vessels are part of this self-limiting process since they
include proteinase inhibitors which are transferred from the
circulation to the site of inﬂammation [25]. This is not the
only feature leading to resolution of the inﬂammatory reac-
tion. Neutrophils have a short lifespan of a few hours, and
the removal of apoptotic neutrophils by macrophages helps
to minimize and prevent any permanent damage caused by
neutrophilic inﬂammation [26]. Our data also supported this
scavenger role of macrophages, as their numbers steadily
increased in BAL over the ﬁrst week period following immu-
nization (Fig. 1D).
Taken together, the ﬁrst part of our study clearly demon-
strated that the production of pro-inﬂammatory cytokines
and subsequent inﬂux of inﬂammatory cells was limited
in duration and magnitude following pulmonary inﬂuenza
vaccination, while its immunogenic effect was maintained.
However, another critical issue is the question if and how
pulmonaryvaccinationmayaffectpre-existinginﬂammatory
diseases in the lung, such as bronchial asthma, which we
tried to answer in the second part of our study.
Utilizing a well established murine model for allergen-
induced airway disease, we demonstrated that pulmonary
inﬂuenza vaccination did not signiﬁcantly exacerbate the
cardinal features of asthma, i.e., the allergen-speciﬁc IgE
formation, the development of AHR and eosinophilic air-
way inﬂammation [27]. AHR and OVA-speciﬁc IgE were
even reduced when compared to unvaccinated allergen-
sensitized/challenged mice (PBS/OVA/PBS) (Figs. 5 and 8),
corroborating previous ﬁndings [28]. This was, for OVA-
speciﬁc IgE, in strong contrast to the LPS-treated
allergen-sensitized control animals that showed signiﬁcantly
increased OVA-speciﬁc IgE values. Studies by Tulic and
co-workers [29] showed that LPS directly stimulated par-
ticularly those B cells which have been primed to produce
IgE, if isotype switch has already occurred, i.e., at least 6
days following allergen-sensitization.
In contrast to its exacerbating effect on IgE pro-
duction, LPS treatment completely abrogated the devel-
opment of increased airway reactivity in allergen-
sensitized/challenged animals. This has already been
described [29] and has been shown to be associated with
LPS stimulation of Th1 inhibitory cytokines IL-12 and/or IFN-
 [30—32]. Similarly, we previously demonstrated that the
preventive effect of respiratory inﬂuenza vaccination on
OVA-speciﬁc IgE production and development of AHR was
also mediated through the induction of local Th1 production
in response to the i.n. whole virion inﬂuenza priming [28].
This Th1 biased immune response following pulmonary
inﬂuenza vaccination was further illustrated by the pro-
ﬁle of the OVA-speciﬁc IgG subclasses in the serum (data
not shown). Th1 polarization might also be causally related
to the slight neutrophilic inﬂux in the BAL ﬂuid of ﬂu
vaccinated OVA-sensitized/challenged mice (Fig. 6). Such
a causal relationship had already been described for LPS
treatment [29], which exacerbated pulmonary neutrophil
inﬂux in OVA-sensitized/challenged mice similar to the
present study. The slight neutrophilic inﬂux in BAL of OVA-
sensitized/challenged mice 36h after inﬂuenza vaccination
corroborated the inﬁltration observed in non-asthmatic vac-
cinated mice. The latter was shown to be reduced to levels
of normal controls within 7 days post-immunization.
In conclusion, we demonstrated that the immune
response induced by pulmonary inﬂuenza vaccination was
not linked to a long-term upregulation of inﬂammatory
responses or toxic side effects and did not exacerbate pre-
existing allergic airway disease. Our data therefore further
illustrate the promising potential of the pulmonary route for
seasonal vaccination with inactivated split inﬂuenza virus.
We strongly recommend further investigation to pursue this
strategy, e.g., by GLP trials in primates and humans.
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